Voyageur Pharmaceuticals Ltd. News
-
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4 Moving on to Stage 2 of the Alberta Innovates AICE-Market Access Program …
-
Voyageur Pharmaceuticals Announces Collaboration with Bayer
February 23, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) a Canadian developer of…
-
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
January 12, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian developer…
-
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
November 7, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developer…
-
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
October 29, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian public company…
-
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
October 23, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF), (the “Company” or “Voyageur”) a Canadian developer…
-
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
August 25, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”) is pleased…
-
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
August 21, 2025 (Source) — TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a radiology…
-
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
August 19, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a company with…
-
Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit
August 18, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”), is pleased to…
